A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

• Status: Terminated
• Trial end date: 2020-06-18

Summary

This was an open-label, multicenter study designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in participants with relapsed or refractory (R/R) multiple myeloma (MM) who received at least 1 prior line of therapy with documented evidence of progression during or after the participant's last treatment regimen. The study was designed to consist of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). For Part 2 the participants were to be divided into 2 cohorts, participants positive for t(11;14) translocation and participants negative for t(11;14) translocation.

• Phase: Phase 2

Details

• Lead Sponsor: AbbVie
• Collaborator: Celgene
• Treatments: BB 1101; Dexamethasone; Dexamethasone acetate; Pomalidomide; Thalidomide; Venetoclax